Laurus Labs has announced the acquisition of a 60% controlling stake in Canada-based Galenvs Sciences for USD 3.75 million. The deal, involving a mix of primary and secondary share purchases, aims to boost the Indian drug maker’s R&D capabilities in oligonucleotide synthesis and magnetic-nanoparticle technology. This move is part of the company's broader effort to expand its footprint in the North American market and strengthen its CDMO offerings.
Laurus Labs to Acquire 60% Stake in Canada's Galenvs Sciences
USD 3.75 million total investment with USD 2.75 million as primary subscription.
60% equity stake acquisition expected to close within the current financial year.
Reader Takeaway: Expansion into North American R&D bolsters CDMO capabilities, though integration across borders remains a key execution test.
What just happened
Laurus Labs has received board approval to acquire a 60% equity stake in Galenvs Sciences, a Canadian contract research organization. The deal is structured through two tranches: a USD 2.75 million primary subscription and a USD 1.00 million secondary acquisition. The company has funded the investment through internal cash reserves and retains an option to acquire the remaining stake from the founder based on future performance milestones.
Why this matters
Galenvs Sciences specializes in custom oligonucleotide synthesis and functional magnetic-nanoparticle technologies. By bringing this R&D pipeline in-house, Laurus Labs intends to accelerate its business development in the specialized diagnostics and therapeutics market. The acquisition serves as a strategic entry point for Laurus Labs into the North American landscape, providing access to proprietary process IP and technical know-how.
Risks to watch
As with all cross-border acquisitions, the primary challenge lies in the integration of foreign technology and personnel. The transaction remains subject to customary closing conditions and final agreements. Investors should monitor the timeline for deal completion and the ability of Laurus Labs to translate Galenvs' R&D pipeline into significant commercial revenue in the coming quarters.
Context metrics
Galenvs Sciences reported turnover of Canadian $ 1.36 million in 2023 and Canadian $ 1.28 million in 2024, with projections of Canadian $ 1.65 million for 2025.